Logotype for Futura Medical plc

Futura Medical (FUM) investor relations material

Futura Medical H1 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Futura Medical plc
H1 2025 earnings summary30 Sep, 2025

Executive summary

  • Interim CEO appointed in August 2025, launching a strategic and performance review to address underperformance, cost structure, and leadership succession.

  • H1 2025 saw launches in up to 25 countries, but consumer uptake and repeat sales were significantly below expectations, especially in the US and Europe.

  • Strategic review underway, focusing on cost-cutting, operational efficiency, and exploring options such as licensing, divestments, asset sales, and new partnerships.

  • New product development (Eroxon Intense, WSD4000) continues, with regulatory milestones targeted for late 2025 and launches expected from 2026 onward.

Financial highlights

  • H1 2025 revenue was £1.0–£1.01 million, with about half from US royalties and half from EU/UK sales; minor contributions from LATAM and Middle East.

  • Gross profit was £0.7–£0.73 million before a £0.49 million inventory obsolescence provision; gross profit after provision was £0.243 million.

  • Exceptional charges totaled £3.6–£4.05 million, mainly for impairment of plant/equipment and inventory write-downs.

  • Loss after tax was £6.59–£6.6 million; adjusted loss after tax (excluding exceptional and non-cash items) was £1.9–£2.0 million.

  • Cash at period end was £3.69 million, falling to £2.7–£2.71 million by end of August 2025, providing runway into January 2026.

  • Full year 2025 revenue now expected between £1.3–£1.4 million, well below initial forecasts.

Outlook and guidance

  • FY 2025 performance and revenue expected to be significantly below market expectations.

  • Cash runway extends into January 2026; further extension depends on commercial or financing actions.

  • Strategic review results and business update expected by end of Q1 2026.

  • Regulatory approval for Project Intense targeted by end of 2025, earliest launch in Q3/Q4 2026; WSD4000 launch anticipated in latter half of 2028.

  • US patent milestone payment delayed to H1 2026, impacting cash flow.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Futura Medical earnings date

Logotype for Futura Medical plc
H2 202514 Apr, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Futura Medical earnings date

Logotype for Futura Medical plc
H2 202514 Apr, 2026

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Futura Medical plc is a UK-based pharmaceutical company developing topical products for sexual health and pain relief. The company uses proprietary transdermal delivery technologies to create over-the-counter and prescription products. It focuses on regulatory approvals and commercial partnerships for global distribution. It is headquartered in Guildford, United Kingdom, and its shares are listed on the LSE.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage